cancer peptide vaccine

2 trials

Sponsors

Kato Naoya, Department of Clinical Oncology, Kawasaki Medical School

Conditions

Hepatocellular carcinoma Cancer peptide vaccineIncurable lung, esophageal, colorectal, gastric, gallbladder, or breast cancer

Phase 1

A Phase I Study of CYT001

Active, not recruitingJPRN-jRCT2031190072

Kato NaoyaHepatocellular carcinoma Cancer peptide vaccine

Start: 2020-05-01Target: 6Updated: 2026-06-29

Unknown Phase

Clinical efficacy of novel cancer vaccines

Active, not recruitingJPRN-UMIN000009167

Department of Clinical Oncology, Kawasaki Medical SchoolIncurable lung, esophageal, colorectal, gastric, gallbladder, or breast cancer

Start: 2012-12-01Target: 100Updated: 2026-06-29

Related Papers

Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).

Journal of Clinical Oncology2020-02-012 citations